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 Introduction 
 Inpatient care accounts for approximately one third of 
all health care costs for dermatological disorders in the 
USA, the proportion of cost for inpatient care being one 
quarter for bullous diseases, one sixth for drug eruptions 
and less than half a percent for psoriasis  [1] . Navarini et 
al.  [2] estimated the costs for inpatient care in Switzerland 
of psoriasis patients to be CHF 60 million (USD 65 mil-
lion) in 2010.
 Since 2012, inpatient medical care in Switzerland for 
acute somatic cases, including dermatological disorders, 
are reimbursed with a diagnosis-related group (DRG)-
based prospective payment system called SwissDRG. 
University medical centers (UMCs) have had to face the 
radical change in reimbursement, from a per diem basis 
to a more or less fixed lump fee per DRG.
 Elsewhere, DRG-based reimbursement systems have 
been implemented for some time and their impact on
inpatient dermatology has been evaluated, especially in 
Germany. The most notable changes were a significant 
decrease in length of stay (LOS), an increase in hospital 
admissions and a moderate increase in average age  [3, 4] . 
In particular, Wenke et al.  [4] could show a reduction in 
mean LOS from 18.2 days (standard deviation, SD ±9.0) 
to 15.6 days (SD ±7.2) for psoriasis patients and from 15.8 
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 Abstract 
 Background: Since 2012, Swiss inpatient dermatology is 
funded through a flat rate payment system based on diag-
nosis-related groups (DRGs).  Objective: To analyze the reim-
bursement of nonsurgically treated severe disorders of the 
skin under the system called SwissDRG.  Methods: Three ret-
rospective, cross-sectional cohort studies were performed. 
Data sets were received from the Swiss Federal Office of Sta-
tistics (1,285,685 retained records), the five Swiss university 
hospitals (370,964 retained records) and our center (72,211 
retained records).  Results: Cases accounted for 0.04% of all 
hospitalizations nationwide, with 43.7% treated at university 
hospitals. Treatment at university hospitals produced a 
mean loss of USD 3,711 per case. Lyell syndrome cases were 
especially underfunded (mean loss USD 31,906). Extra-coun-
ty admissions and direct referrals were significant predictors 
of total inpatient costs (p = 0.019 and p < 0.001, respectively). 
 Conclusions: We suggest grouping Lyell syndrome cases 
into burn DRGs and evaluating extra-county admissions and 
direct inpatient referrals as DRG split criteria. 
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days (SD ±13.3) to 10.3 days (SD ±10.2) for bullous der-
matoses in a 4-year period from the introduction of DRGs 
in Germany in 2003 to 2006. Moreover, a decrease in al-
lergy provocation tests in an inpatient setting in German 
UMCs was noted between 2008 and 2010  [5] . Nonethe-
less, the homogeneity of German dermatological DRGs 
upon introduction in 2003 was far from perfect and 
changes were necessary, affecting also DRG grouping of 
severe, nonsurgically treated operative disorders of the 
skin  [6] .
 The aim of our study was to analyze the reimburse-
ment of nonsurgically treated, severe disorders of the skin 
under SwissDRG and, where deemed appropriate, to 
amend changes. We focused on erythematosquamous or 
bullous skin disorders, including psoriasis, pityriasis ru-
bra pilaris, pemphigoid disorders, and erythema exudati-
vum multiforme (EEM)/Lyell syndrome.
 Materials and Methods 
 We designed three retrospective, cross-sectional cohort studies 
based on the Swiss national medical data set from the Federal Of-
fice of Statistics (FOS) on cost and coding data of the five Swiss 
UMCs (University Hospital of Zurich – our institution –, CHUV 
Lausanne, University Hospital of Geneva, Inselspital Bern and 
University Hospital of Basel) as well as from cost, coding and ad-
ministrative data from our center.
 Psoriasis cases were selected with a main ICD-10 diagnosis L40, 
pemphigoid cases with ICD-10 L12, EEM/Lyell-syndrome with 
ICD-10 L51 and other erythematosquamous skin disorders in-
cluding pityriasis rubra pilaris with ICD-10 L44.
 The number of inpatient cases for the aforementioned disor-
ders and the proportion of cases treated at university centers were 
calculated with the national medical data set of all hospitalized
patients from the year 2012 provided by the FOS, comprising 
1,353,521 data sets of hospital records (988,694 patients). After 
excluding erroneous data sets (statistic case B or C, patient ID = 0 
or time since last hospitalization in days being an empty field or 
negative number), 1,285,685 case records (967,263 patients) were 
retained for further analysis ( fig. 1 a). Case fusions were not taken 
into account.
n = 370,964
Inpatient records
Discharged 2012–2013
from a Swiss university
medical center
n = 1,353,521
Swiss inpatient
records
n = 515
Main diagnosis
psoriasis, bullous
pemphigoid, EEM
or other
papulosquamous
disorder
n = 1,285,685
Inpatient records
retained
n = 443
Main diagnosis
psoriasis, bullous
pemphigoid, EEM
or other
papulosquamous
disorder
n = 348
DRG J61B
a b
n = 73,211
Inpatient records
Discharged 2012–2013
from the University
Hospital of Zurich
n = 4,015
Cases with a DRG 
classifying into a skin or
breast DRG
(MDC 09)
n = 1,351
Nonsurgical cases
c
 Fig. 1. Flowchart of study designs.  a First study. Selection of a total of 515 inpatient cases discharged from Swiss 
hospitals in 2012. Data obtained from the FOS, Switzerland.  b Second study. Respective analysis of 443 and 348 
cases discharged from a Swiss university hospital in 2012 or 2013.  c Third study. Selection of 1,351 nonsurgical 
cases classifying into a dermatological DRG (MDC 09). 
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 We obtained the data from the permanent task force of the fi-
nancial departments of all five Swiss UMCs (UNIFIN). In total, 
370,964 case records with discharges in 2012 or 2013 were includ-
ed in our analysis ( fig. 1 b).
 For the analysis of innovative predictors for inpatient treat-
ment costs, we analyzed 72,211 records from our center with dis-
charges in 2012 or 2013 ( fig. 1 c). In total, 1,351 nonsurgical cases 
classifying into the major diagnostic category of diseases of the 
cutis, subcutis or mamma (major diagnostic category, MDC, 09) 
were retained.
 Diagnoses were coded according to ICD-10-GM. The same na-
tional coding regulations applied to all hospitals. Coding was sub-
ject to independent external audits. UNIFIN records were coded 
with the SwissDRG web-based grouper for the year 2014 (version 
3.0). A base rate of CHF 11,200 per case mix point was assumed 
for our calculations. Additional payments (‘Zusatzentgelte’) were 
not taken into account.
 The costs analyzed were the total costs per case obtained from 
the UNIFIN data set and our hospital accounting data set. Total 
costs per case were the case-based individual costs determined by 
the full cost accounting method proscribed by national accounting 
guidelines for inpatient care institutions (REKOLE ®  [7] ), which is 
in place in all Swiss hospitals. The format of the data set for case 
costs was identical with the format submitted to SwissDRG. A con-
version rate of CHF 1 to USD 1.08 was assumed. The DRGs ana-
lyzed in the national data set were the actual DRGs of 2012 sub-
mitted to the FOS (SwissDRG version 1.0).
 Data sets were processed by the business intelligence software 
QlikView ® and exported to Microsoft Excel ® for further analysis. 
Statistical analysis was done with IBM SPSS Statistics version 22 
 [8] . Significance was tested with the Mann-Whitney test. Results 
with p < 0.05 were considered significant.
 The cost homogeneity coefficient (CH) for a DRG was calcu-
lated according to the formula CH = 1/(1 + σ/μ), where σ = SD
and μ = arithmetic mean  [9] .
 The local Institutional Review Board (Ethics Committee of the 
Canton of Zurich) gave its approval for our study.
 Results 
 A total of 515 inpatient cases of severe skin disorders 
were recorded in the Swiss national database for inpatient 
medical records. These comprised 285 psoriasis cases 
(55.7%), 132 cases of bullous pemphigoid (25.9%), 75 cas-
es of EEM/Lyell syndrome (14.6%), and 23 cases with oth-
er erythematosquamous disorders including pityriasis 
rubra pilaris (4.5%;  table  1 ;  fig.  2 a). Overall, 225 cases 
were treated at a UMC (43.7%) and a further 144 at a
hospital providing full health care coverage other than
a UMC (28.0%;  table 1 ;  fig. 2 b). Hence, these disorders 
accounted for 0.04% of inpatient cases in Switzerland in 
2012 and were mostly treated in hospitals offering full 
medical services. In total, 62.1% were classified into the 
DRG J61B (n = 320), 9.5% into the DRG I66D (n = 49) 
and 8.3% into the DRG J61C (n = 43). For details, see on-
line suppl. table 1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000437223). We assumed that 
the average cost for cases classifying as DRG J61B in the 
FOS statistic would be the most accurate approximation 
for total inpatient costs for our cohort. The reported aver-
age total cost per case was CHF 12,391 (SD 11,119; mean 
USD 13,382 ± 12,008)  [10] , amounting to a total of
CHF 6,381,210 (SD 5,726,031; mean USD 6,891,706
 Table 1.  Inpatient cases of psoriasis, bullous pemphigoid, EEM/Lyell or other papulosquamous disorders such as pityriasis rubra pilaris 
in Switzerland 2012
Total
(n = 515)
Bullous
pemphigoid
(n = 132)
EEM/Lyell
(n = 75)
Other papulo-
squamous 
disorders (n = 23)
Psoriasis
(n = 285)
Hospital type
UMC 225 (43.7%) 71 (53.8%) 24 (32.0%) 9 (39.1%) 121 (42.5%)
Full medical care provider (non-UMC) 144 (28.0%) 49 (37.1%) 27 (36.0%) 10 (43.5%) 58 (20.4%)
Hospital providing basic care 50 (9.7%) 9 (6.8%) 21 (28.0%) 2 (8.7%) 18 (6.3%)
Psychiatry 1 (0.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.4%)
Rehabilitation institution 5 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (1.8%)
Specialized center 90 (17.5%) 3 (2.3%) 3 (4.0%) 2 (8.7%) 82 (28.8%)
LOS, days 10 (5 – 19) 10 (7 – 15) 6 (2 – 10) 9 (3 – 19) 11 (6 – 21)
Age, years 62 (45 – 75) 82 (74 – 88) 48 (20 – 64) 68 (29 – 75) 54 (43 – 65)
Female 232 (45.0%) 65 (49.2%) 32 (42.7%) 12 (52.2%) 123 (43.2%)
Days since last inpatient treatment 41 (0 – 552) 97 (0 – 598) 1 (0 – 414) 16 (0 – 91) 31 (0 – 625)
Last inpatient discharge <1 day 214 (41.6%) 34 (25.8%) 37 (49.3%) 10 (43.5%) 133 (46.7%)
 Results are presented as absolute values (%) for nominal variables and as medians (interquartile ranges) for continuous variables.
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± 6,184,114) for inpatient care for these four dermato-
logical diseases.
 In a second step, we wanted to analyze the cost struc-
ture and reimbursement of these skin disorders treated 
at UMCs. We therefore searched all medical records 
from Swiss patients discharged in 2012 or 2013. Of 
370,964 cases, 443 were retained ( table 2 ). Patients with 
bullous pemphigoid were on average the oldest. The co-
hort with other erythematosquamous disorders had the 
longest LOS. With 2,329 case mix points, the cohort of 
cases with EEM/Lyell syndrome had a case mix index ap-
proximately twice as high as the cohorts with the other 
cutaneous disorders. With an average cost of CHF 34,548 
(SD 56,196; mean USD 37,312 ± 60,692), they were also 
the most expensive to treat and with an average loss of 
CHF 8,466 (SD 19,677; mean USD 9,143 ± 21,251) – the 
disorder with the largest underfunding. In total, an aver-
age case was treated at a loss of CHF 3,436 (SD 10,270; 
Inpatient care provider type
Distribution of main diagnosis
UMCs
Full health care services other
than UMCs
Hospitals providing basic care
Specialized clinics
Psychiatry
Rehabilitation clinic
Psoriasis
Bullous pemphigoid
EEM/Lyell syndrome
Other papulosquamous
disorders
a
b
 Fig. 2. Inpatient care for severe derma-
tological disorders in Switzerland, 2012. 
Analysis of cases with a main diagnosis of 
psoriasis, bullous pemphigoid, EEM/Lyell 
syndrome or other erythematosquamous 
disorders such as pityriasis rubra pilaris
(n = 515).  a Distribution of cases according 
to hospital type.  b Distribution of cases ac-
cording to main diagnosis. 
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mean USD 3,711 ± 11,092). A total of 79% were inliers, 
12% were high outliers by LOS and 67% were grouped 
into the DRG J61B.
 As the majority of cases were grouped into the J61B, 
we subsequently analyzed the discharges from all five 
centers with this particular DRG. Of 370,964 cases, 348 
were retained. Results are summarized in  table 3 and  fig-
ure 3 . The most frequent pathology was psoriasis (41.7%) 
followed by bullous pemphigoid (32.5%). Hospital 1 had 
a remarkably high proportion of psoriasis patients (61.3%) 
 Table 2.  Main diagnosis of nonsurgically treated severe skin disorder: discharges from all 5 UMCs 2012 – 2013
Total
(n = 443)
Bullous
pemphigoid
(n = 148)
EEM/Lyell
syndrome
(n = 51)
Other
papulosquamous
disorders
(n = 18)
Psoriasis
(n = 226)
Female 193 (43.6%) 72 (48.6%) 20 (39.2%) 9 (50.0%) 92 (40.7%)
Age, years 63 (46 – 77) 81 (72 – 85) 34 (20 – 54) 63 (43 – 71) 55 (43 – 66)
LOS, days 9.0 (6.0 – 16.0) 10.0 (6.5 – 16.0) 8.0 (5.0 – 14.0) 13.5 (9.0 – 24.0) 9.0 (5.0 – 15.0)
Case weight, points 1.294 (1.423) 1.201 (0.526) 2.329 (2.852) 1.246 (0.477) 1.126 (0.450)
DRG revenue per case, CHF 14,498 (15,933) 13,452 (5,888) 26,082 (43,147) 13,960 (5,342) 12,612 (5,045)
Total costs per case, CHF 17,934 (22,866) 19,005 (15,255) 34,548 (56,196) 17,349 (8,563) 13,530 (9,216)
Earnings per case, CHF –3,436 (10,921) –5,553 (11,618) –8,466 (19,677) –3,389 (4,919) –918 (6,571)
Inliers 348 (78.6%) 123 (83.1%) 41 (80.4%) 12 (66.7%) 172 (76.1%)
High outliers 55 (12.4%) 19 (12.8) 2 (3.9%) 6 (33.3%) 28 (12.4%)
Low outliers 29 (6.5%) 3 (2.0%) 3 (5.9%) 0 (0%) 23 (10.2%)
 Cases with deduction due to direct
referral from another hospital 11 (2.5%) 3 (2.0%) 5 (9.8%) 0 (0%) 3 (1.3%)
DRG J61B 297 (67.0%) 113 (76.4%) 25 (49.0%) 14 (77.8%) 145 (64.2%)
 Results are presented as absolute values (%) for nominal variables and as means (SD) for continuous variables. Age and LOS are pre-
sented as medians (interquartile ranges).
 Table 3.  DRG J61B: discharges from all 5 UMCs 2012 – 2013
Total Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5
(n = 348) (n = 119) (n = 114) (n = 55) (n = 42) (n = 18)
Main diagnosis
Psori asis 145 (41.7%) 73 (61.3%) 43 (37.7%) 12 (21.8%) 11 (26.2%) 6 (33.3%)
Bullous pemphigoid 113 (32.5%) 21 (17.6%) 45 (39.5 %) 24 (43.6%) 17 (40.5%) 6 (33.3%)
EEM/Lyell 25 (7.2%) 7 (5.9%) 6 (5.3%) 8 (14.5%) 4 (9.5%) 0 (0.0%)
Other papulosquamous
disorders 14 (4.0%) 11 (9.2%) 1 (0.9%) 0 (0.0%) 0 (0.0%) 2 (11.1%)
Other 51 (14.7%) 7 (5.9%) 19 (16.7%) 11 (20.0%) 10 (23.8%) 4 (22.2%)
Age, years 66 (49 – 79) 59 (45 – 73) 68 (51 – 80) 69 (43 – 82) 74 (54 – 83) 73 (54 – 84)
Female 160 (46.0%) 53 (44.5%) 51 (44.7%) 27 (49.1%) 23 (54.8%) 6 (33.3%)
LOS, days 9.0 (6.0 – 15.0) 15.0 (9.0 – 18.0) 6.0 (4.0 – 8.0) 9.0 (6.0 – 14.0) 10.0 (7.0 – 15.0) 13.5 (7.0 – 19.0)
Case mix points 1.115 (0.347) 1.192 (0.427) 1.006 (0.114) 1.092 (0.351) 1.184 (0.423) 1.210 (0.381)
Total case costs, CHF 15,772 (12,453) 16,953 (11,520) 10,910 (5,553) 17,183 (14,036) 23,099 (20,089) 17,358 (11,405)
DRG revenue per case, CHF 12,490 (3,891) 13,347 (4,783) 11,267 (1,275) 12,233 (3,931) 13,260 (4,738) 13,551 (4,267)
Earnings per case, CHF –3,283 (10,270) –3,606 (9,607) 357 (5,307) –4,950 (11,520) –9,839 (16,219) –3,807 (7,999)
DRG status
Inliers 289 (83.0%) 91 (76.5%) 103 (90.4%) 46 (83.6%) 35 (83.3%) 14 (77.8%)
High outliers 41 (11.8%) 26 (21.8%) 0 (0.0%) 4 (7.3%) 7 (16.7%) 4 (22.2%)
Low outliers 12 (3.4%) 0 (0.0%) 9 (7.9%) 3 (5.5%) 0 (0%) 0 (0.0%)
Cases with referral 6 (1.7%) 2 (1.7%) 2 (1.8%) 2 (3.6%) 0 (0.0%)
 Results are presented as absolute values (%) for nominal variables and as means (SD) for continuous variables. Age and LOS are presented as medians 
(interquartile ranges).
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and a remarkably low proportion of bullous pemphigoid 
cases (17.6%). Hospital 2 was the only center without high 
outliers and had 7.9% low outliers. It was also the only 
center treating cases at full cost coverage, with a mean of 
CHF 357 (SD 5,307; mean USD 386 ± 5,732).
 The coefficient of homogeneity for all J61B cases dis-
charged from the five UMCs was 55.9%. When only the 
inliers were retained (n = 289), the coefficient of homo-
geneity amounted to 63.2%, with a mean of CHF 13,279 
(SD 7,734; mean USD 13,341 ± 8,353). When including 
inliers only, the distribution of total costs per case was 
skewed to the right (skewness 3.215, SD 0.143). Graphical 
tests for normality of cost distribution are shown in on-
line supplementary figure 1.
 We then took a closer look at the 51 cases of EEM/
Lyell syndrome. Amongst those cases, 11 were Lyell syn-
100
80
60
40
20
120
0
N
um
be
r o
f c
as
es
To
ta
l c
os
ts
 p
er
 c
as
e 
(C
H
F)
Ea
rn
in
gs
 p
er
 c
as
e 
(C
H
F)
100
80
60
40
20
120
0
N
um
be
r o
f c
as
es
4321 5
Hospital
4321 5
Hospital
80,000
60,000
40,000
20,000
100,000
0
0
–20,000
–40,000
–60,000
20,000
–80,000
4321 5
Hospital
4321 5
Hospital
Main diagnosis
Bullous pemphigoid
EEM/Lyell
Other
Other papulosquamous
disorders
Psoriasis
DRG status
Inliers
High outliers
Low outliers
Referral deduction
a
c d
b
 Fig. 3. Analysis of the DRG J61B. Discharges from 2012 and 2013 
from any of the 5 Swiss university hospitals (n = 348).  a Distribu-
tion of cases by main diagnosis at the 5 centers.  b Distribution of 
LOS status at the 5 centers.  c Distribution of total treatment costs 
at the 5 centers.  d Distribution of earnings at the 5 centers. Bar 
charts: the numbers of cases are shown as absolute values. Box 
plots: the upper and lower bounds of the boxes indicate the 75th 
and 25th percentiles, respectively; the broad line in the box indi-
cates the median. Bars indicate the 5th and 95th percentiles; circles 
and stars indicate outliers. 
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drome, with an average cost per case of CHF 102,220 (SD 
86,371; mean USD 110,398 ± 93,281) and a median LOS 
of 16.0 days (interquartile range 6.5–33.5 days). The aver-
age loss per case of Lyell syndrome amounted to CHF 
29,542 (SD 27,481; mean USD 31,906 ± 29,680;  table 4 ; 
 fig. 4 ).
 In a last step, we searched for other predictors for high 
cost cases. Therefore, we analyzed all nonsurgical cases 
classifying into a skin or breast DRG (MDC 09) dis-
charged from our center ( table 5 ). A county of residence 
different to that of our center or a direct referral from
another hospital were significant predictors for total cost 
(p = 0.019 and p < 0.001, respectively). Discharges to re-
habilitation centers showed a strong tendency to being 
more expensive to treat, although results were not sig-
nificant (p = 0.055).
 Discussion 
 A proportion of 0.04% of all inpatient hospitalizations 
in Switzerland in 2012 were cases with a primary diag-
nosis of psoriasis, bullous pemphigoid, EEM/Lyell syn-
drome, or other erythematosquamous disorder. A total of 
43.7% were treated at university hospitals. We estimated 
the inpatient treatment cost at CHF 6.4 million (USD 6.9 
million). Our study cannot confirm the inpatient treat-
ment costs for psoriasis in Switzerland published by
Navarini et al.  [2] in 2010. Assuming half of our estimat-
ed treatment costs were due to psoriasis cases (55.6% of 
total cases), the discrepancy in the estimated nationwide 
inpatient disease burden was 20-fold. One reason could 
be that our study selected cases only by main diagnosis. 
Indeed, Navarini et al. published a total of 3,578 cases 
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 Fig. 4. Analysis of the DRG J61B differentiated for Lyell syndrome 
as the main diagnosis (L51.2). Discharges from 2012 and 2013 
from any of the 5 Swiss university hospitals (n = 348).  a Distribu-
tion of LOS.  b Distribution of total treatment costs per case.  c Dis-
tribution of earnings per case. Box plots: the upper and lower 
bounds of the boxes indicate the 75th and 25th percentiles, respec-
tively; the broad line in the box indicates the median. Bars indicate 
the 5th and 95th percentiles; circles and stars indicate outliers. 
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with psoriasis diagnosis in 2004. As the main diagnosis 
reflects the primarily treated morbidity, we assume that 
our cost estimation is more realistic. Our assumption is 
confirmed by Bickers et al.  [1] , who published inpatient 
treatment costs for psoriasis in the USA of USD 6 million, 
in a country with a population 40 times larger. However, 
it is important to state that hospitalization for psoriasis in 
the USA is much less frequent than in Europe  [11] . Near-
ly two thirds of the cases were grouped into the DRG 
J61B.
 Psoriasis was the most common disorder treated at 
any of the five UMCs in 2012–2013, accounting for just 
over half the cases (51.0%). Patients with bullous pemphi-
goid were on average the oldest (median age 81 years); 
other erythematosquamous disorders such as pityriasis 
rubra pilaris were on average hospitalized for the longest 
(median 13.5 days). Cases with EEM/Lyell syndrome 
were the most expensive and were also the most under-
funded, with a mean cost of CHF 34,548 (USD 37,312) 
and a mean loss of CHF 8,466 (USD 9,143). This was due 
to the 11 cases of Lyell syndrome. This subcohort had a 
median LOS of 16.0 days, mean treatment costs of CHF 
102,220 and an underfunding of CHF 29,542. This is not 
surprising, as cases with Lyell syndrome require com-
pletely different care and are treated as severe burns in 
specialized intensive care units. We therefore advocate 
 Table 4.  Severe dermatological disorders differentiated for the main diagnosis of Lyell syndrome: discharges
from all 5 UMCs 2012 – 2013
Total
(n = 443)
Non-Lyell syndrome
(n = 432)
Lyell syndrome
(n = 11)
Age, years 63 (46 – 77) 63.5 (47 – 77) 45 (28 – 74)
Female 193 (43.6%) 187 (43.3%) 6 (54.5%)
LOS, days 9.0 (6.0 – 16.0) 9.0 (6.0 – 16.0) 16.0 (5.0 – 35.0)
Total costs per case, CHF 17,934 (22,866) 15,788 (12,644) 102,220 (90,587)
DRG revenue per case, CHF 14,498 (15,933) 13,017 (6,025) 72,678 (76,407)
Total earnings per case, CHF –3,435 (10,921) –2,771 (9,230) –29,542 (28,823)
p value <0.001
 Results are presented as absolute values (%) for nominal variables and as means (SD) for continuous variables. 
Age and LOS are presented as medians (interquartile ranges).
 Table 5.  Predictors of total costs in nonsurgical, dermatological DRGs (MDC 09, partition M): discharges from our center 2012 – 2013
Total
(n = 1,341)
Patients from
the same 
county
(n = 988)
Patients from
a different
county
(n = 363)
Not referred
from another
hospital
(n = 1,307)
Referred
from another
hospital
(n = 44)
Not discharged
to rehabilitation 
center
(n = 1,341)
Discharged to
rehabilitation
center 
(n = 10)
Age, years 56 (41 – 72) 58 (41 – 74) 54 (39 – 68) 56 (41 – 72) 52.5 (40.5 – 81.5) 56 (41 – 72) 69.5 (40 – 77)
Female 672 (49.7%) 492 (49.8%) 180 (49.6%) 653 (50.0%) 688 (49.8%) 4 (40.0%)
LOS, days 5.0 (2.0 – 11.0) 5.0 (2.0 – 10.0) 6.0 (2.0 – 12.0) 5.0 (2.0 – 11.0) 8.0 (3.0 – 13.5) 5.0 (2.0 – 11.0) 13.5 (3 – 16)
Psoriasis, bullous 
pemphigoid, other 
papulosquamous, 
EEM/Lyell 122 (9.0%) 81 (8.2%) 41 (11.3%) 114 (8.7%) 8 (18.2%) 119 (8.9%) 3 (30.0%)
Tumor 218 (16.1%) 130 (13.2%) 88 (24.2%) 215 (16.4%) 3 (6.8%) 217 (16.2%) 1 (10%)
Total costs per case, CHF 9,011 (7,901) 8,647 (7,257) 10,003 (9,372) 8,771 (7,471) 16,153 (14,513) 8,978 (7,891) 13,511 (8,373)
DRG revenue per case, CHF 7,927 (4,425) 7,725 (4,432) 8,475 (4,366) 7,910 (4,428) 8,430 (4,362) 7,909 (4,422) 10,338 (4,489)
Earnings per case, CHF –1,085 (5,510) –922 (4,713) –1,527 (7,238) –861 (4,992) –7,722 (12,227) –1,069 (5,512) –3,173 (5,054)
p value 0.019 <0.001 0.055
 Results are presented as absolute values (%) for nominal variables and as means (SD) for continuous variables. Age and LOS are presented as medians 
(interquartile range).
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excluding cases with a main diagnosis of Lyell syndrome 
(ICD-10 L51.2-) from the dermatological DRGs (MDC 
09) and including these cases into burn DRGs (MDC 22). 
Cost coverage could be achieved by grouping Lyell syn-
drome cases into the DRG Y01Z.
 For historical reasons, the diagnosis of Lyell syndrome/
Stevens-Johnson syndrome on the one hand, as well as 
EEM on the other hand, are listed under the same diag-
nostic family L51  [12] . However, evidence has shown that 
EEM is a different clinical entity to Stevens-Johnson syn-
drome and Lyell syndrome, with the former being linked 
to herpes virus infections, whereas Stevens-Johnson syn-
drome and Lyell syndrome form a continuum of severity 
of the same disease linked to severe pharmacoimmuno-
logical reactions  [13, 14] . We grouped the cases due to 
ICD similarity. However, the difference in financial re-
sults reflecting the strong difference in treatment require-
ments further underlines the difference between these 
two separate disease entities.
 We were surprised by the fact that 28% of EEM/Lyell 
cases in Switzerland in 2012 were treated at hospitals pro-
viding basic care in comparison to fewer than 10% for all 
other diseases. We explain this by the fact that EEM-Lyell 
has a very acute onset, sometimes manifesting itself dur-
ing hospitalization, and is treated regionally without re-
ferral to specialized dermatological inpatient depart-
ments.
 The DRG J61B shows a wide and strongly right-skewed 
cost distribution. Including outliers, the cost homoge-
neity coefficient was low at 55.9%. Considering inlier
cases only, we calculate a cost homogeneity coefficient of 
62.3%. We therefore conclude that J61B is not homoge-
nous for costs at a UMC level and warrants improvement. 
Referral from other hospitals and extra-county admis-
sions were two variables significantly predicting total cost 
for nonsurgical, dermatological cases. We therefore sug-
gest testing these variables for their possibility of use as 
split criteria within the Swiss DRG system.
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